Respiratory imaging technology company 4DMedical Limited (ASX:4DX) has confirmed the commencement of an important US-based clinical pilot, with first scans occurring at Providence St. Joseph Hospital in Orange, California.
This pilot represents the first commercial usage of XV LVAS in the United States (US), with multiple scans across a range of conditions including COPD and long-COVID already completed.
This pilot is being conducted at Providence St. Joseph Hospital in Orange County, California. St. Joseph Hospital is one of 52 hospitals within the Providence Health & Services network, the third largest not-for-profit health system in the US.
These successful scans at St. Joseph Hospital build on previous and concurrent use of XV Technology in clinical trials undertaken at other US sites including Johns Hopkins Medical Center, Cleveland Clinic, Vanderbilt University Medical Centre, Duke University Hospital and the University of Miami.
This US pilot is a key milestone in plans to grow 4DMedical’s global footprint 4DMedical has already taken important steps towards entering the Australian market. The company now offers its unique four-dimensional respiratory scans on a commercial basis through the I-MED Radiology Network, the largest provider of medical imaging in Australia.
I-MED adopted 4DMedical’s XV Technology following the successful completion of a clinical pilot programme.
4DMedical is deploying a similar process in the US with the start of the clinical pilot programme at Providence St. Joseph Hospital located in California.
Providence St. Joseph Hospital Chief Executive Dr Jeremy Zoch PhD said the potential for 4DMedical’s XV Technology to play a role in the surveillance of lung function is unprecedented, along with the capacity to monitor the effectiveness of pharmaceutical and other interventions for the treatment of those diseases.
“Doctors have never been able to see lungs with this level of richness and detail before. We’re proud of our commitment to bring the latest in life-changing technology to doctors, patients and community.”
4DMedical Founder, Chief Executive Officer and Chief Technology Officer Dr Andreas Fouras PhD said the pilot will help open the door to the huge US diagnostics market and take the company closer to realising the commercial potential of its innovative technology.
“This progress comes hot on the heels of our recent unveiling of an operational XV Scanner incorporating the company’s proprietary XV Technology. While the US pilot has been slower to get moving than we anticipated, we are excited by the momentum it injects into our commercialisation efforts at this time.
“Its realisation reflects well on the commitment of the whole 4DMedical team to see its way through recent multiple challenges, the COVID-19 pandemic included.
“As the pilot progresses, we expect it will clearly demonstrate that our technology markedly improves doctors’ ability to diagnose and treat a range of respiratory diseases.”
